Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications

... effect. The development of effective brain targeting and delivery technologies, such as ... to protect the use of our NeuroTrans(TM) CNS targeting peptides and the extensive range of potential ... the application of highly specialized drug targeting platforms and formulation expertise. Raptor ...

Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research

... Safety and Efficacy of a tk RNAi Therapeutic targeting Beta-Catenin (CTNNB1) , received special ... tkRNAi therapeutic Presentation targeting the primary oncogene (beta-catenin, CTNNB1) ... present data describing the targeting of chemotherapy resistance with tkRNAi. Here, ...

Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.

... cancers; an inhibitor of Factor VIIa (PCI-27483) targeting pancreatic, gastric, colon and breast cancers; a ... currently in a Phase I clinical trial and targeting B-cell related oncology applications; a Btk inhibitor in advanced preclinical testing (PCI-45261) targeting autoimmune and allergic indications; and an ...

Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference

... an orally administered tk RNAi therapeutic targeting the primary oncogene (beta-catenin, CTNNB1) in ... affected." The study showed that tk RNAi targeting beta-catenin was well tolerated at high dosing ... in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel ...

Raptor Pharmaceuticals Provides Update on Targeting Platforms

... that could increase the utility of RAP-based targeting platforms and potential therapeutics. RAP-based ... and will complement our growing in-house set of targeting peptides." Raptor also announced that the ... company focused on improving drug targeting to expand the reach and benefit of existing ...

Novel Photoconductive Life Science Research Innovation Enables Rapid, Reproducible, and Non-Invasive Cellular Excitation

... electrode arrays). The non-invasive, optical targeting used by the PSD allows for an extended ... without causing damage to the cells while optical targeting enables highly controlled depolarization of only ... which does not allow for specific cell targeting and/or rapid repetitive depolarization, ...

Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab

... trial investigating MT110, a BiTE antibody targeting EpCAM, in patients with lung or gastrointestinal ... advanced non-Hodgkin's lymphoma. MT110, which is targeting EpCAM (CD326) and is the first BiTE antibody ... cancers. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, respectively, are in ...

Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen

... covers the use of antisense compounds targeting the apoB messenger RNA except a ribozyme. "We ... patent covers methods of inhibiting apoB by targeting anywhere on the messenger RNA including the site ... broad filings protecting the therapeutic use of targeting apoB for the lowering of all atherogenic lipids, ...

Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models

... company developing and commercializing products targeting the extracellular matrix, today announced the ... Vice President and Chief Scientific Officer. "By targeting tumors that overproduce the HA matrix component, ... company developing and commercializing products targeting the extracellular matrix for the drug ...

Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia

... (ALL). Blinatumomab is a T cell engaging antibody targeting the CD19 antigen, which is only expressed on B ... CD19 is widely expressed in ALL, no therapies targeting CD19 are currently available," said Professor D. ... BiTE antibody program is MT103 (MEDI-538), targeting CD19, and has provided proof-of-concept in an ...

Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference

... company developing and commercializing products targeting the extracellular matrix, today announced new ... company developing and commercializing products targeting the extracellular matrix for the drug delivery, ... of different enzymes in its portfolio that are targeting significant areas of unmet need. Safe Harbor ...

MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13

... two new trials with a monoclonal antibody (MAb) targeting interleukin-13 (IL-13). One of the studies is a ... MedImmune has multiple approaches in development targeting asthma. Currently, in human testing the company has antibodies targeting IL-9 (MEDI 528) and IL-13 (CAT-354), each in ...

Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing

... UK company focusing on therapeutics targeting PI3-kinase (PI3-K). The PI3-K pathway is known ... by Piramed's two major research programs targeting PI3-K-alpha in oncology and PI3-K-delta in ... resistance to potential chemotherapeutic agents targeting the epidermal growth factor receptor. Pre- ...

Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference

... - New Approach to targeting the Tumor Microenvironment - SAN DIEGO, April ... company developing and commercializing products targeting the extracellular matrix, today announced new ... company developing and commercializing products targeting the extracellular matrix for the drug delivery, ...

Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies

... of its anti-phosphatidylserine (anti-PS) vascular targeting antibodies. The study by Dr. Yayun Liang, Dr. ... anti-cancer potential of our anti-PS vascular targeting platform," said Steven W. King, president and CEO ... Benakanakere, Sandra L. Brandt, Philip E. Thorpe. targeting mutant p53 protein and tumor vasculature: An ...

Study Shows Intradigm's RNAi Nanoplex Technology To Be Effective Systemic siRNA Delivery Platform for the Treatment of Various Cancer Models

... small interfering RNAs (siRNAs) targeting both vascular endothelial growth factor (VEGF) ... of Intradigm. "Furthermore, by effectively targeting VEGF, VEGFR2, and EGFR, three established ... attach a Polyethylene Glycol (PEG) layer and/or a targeting ligand to the polymer-siRNA NPX to improve ...

Raptor Pharmaceuticals Provides Update of Product Programs

... from ongoing preclinical studies of its RAP liver targeting program, Raptor has initiated a pre-IND program for HepTide(TM) (its liver targeting therapeutic conjugate using the RAP targeting ... initiated proof-of-principle preclinical studies targeting a new therapeutic area: the use of the HepTide ...

General Wesley Clark Joins Immtech as Consulting Strategic Advisor

... team as the Company develops its drug programs targeting various global health challenges, including ... is also in two pivotal Phase III trials targeting the treatment of Pneumocystis pneumonia (PCP), a ... a well defined, expanding library of compounds targeting Hepatitis C, fungal infections, and bacterial ...

FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent

... combination of the only approved drug, Tekturna, that works by directly targeting renin and decreasing the activity of the renin angiotensin aldosterone ... a direct renin inhibitor, is the only drug that works by directly targeting renin and decreasing the activity of the RAAS. Renin is an enzyme produced ...

Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimer's Disease

... our pioneering approach to treat or prevent Alzheimer's disease by targeting the proteins that cause the earliest stages of this disease". ... a leader in the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with ...

deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia

... of the disease and making it possible for us to begin to develop drugs targeting the underlying causes and not just the symptoms of the disease. One of the ... for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and ...

PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference

... ultimately results in the persistent inflammation underlying the disease. targeting the CCR9 chemokine receptor represents a novel approach for the treatment ... generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small ...

Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506

... oral tyrosine kinase inhibitor (TKI) with a kinase inhibition profile targeting angiogenic, stromal and oncogenic receptor tyrosine kinases (TK). In ... of tumor cell lines while promoting apoptosis (cell death) by directly targeting several oncogenic TK receptors. The clinical significance of these ...

Isis and Collaborators Present New Research at the ATVB Annual Conference

... showing the ability of antisense drugs in a late-stage research program targeting apoC-III to selectively reduce triglycerides in both liver and blood. ... Finally, Isis and collaborators reported on the effects of antisense drugs targeting 11 beta-HSD1 and apoF. In a presentation titled "Antisense-mediated ...

First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept

... is developing several other drug candidates, all of which have a unique targeting mechanism of action whereby candidates bind specifically and exclusively ... to be resistant to chemotherapeutic drugs, without harming normal cells. targeting occurs through binding to specific receptors on the cell's surface. The ...

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

... "Numerous published clinical and preclinical data suggest that therapies targeting EpCAM such as adecatumumab could prove to be highly effective anti-cancer ... against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of ...

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY

... antibodies in general, but only as markers of indiscriminate targeting of that particular antibody, with the EGFR blockade of normal cells by the ... Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and ...

Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)

... KPC) and class C enzymes. NXL104 in combination with ceftazidime will be targeting infections caused by Gram negative bacteria, including Enterobacteriaceae ... are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $15bn ...

Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial

... agent that is being evaluated for its ability to inhibit angiogenesis by targeting vascular endothelial growth factor receptors 1, 2 and 3 (VEGFR1-3). It is also under investigation for its potential direct anti-tumor activity by targeting a family of proteins called tyrosine kinases, including platelet-derived ...

Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer

... completion of the phase II program also supports Algeta's strategy for targeting Alpharadin at patients with metastatic HRPC who are unsuitable or who have ... placebo-like safety profile. Development of Alpharadin is most advanced targeting bone metastases resulting from hormone-refractory prostate cancer (HRPC), ...

Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2

... designed with the objective of creating a multifunctional inhibitor by targeting a single protein and affecting potentially many cancers. CX-4945 ... serine/threonine protein kinases, as well as innovative nucleolus targeting agents (NTAs) that target the abnormal nucleolar functions of cancer cells ...

Micromet Key Events for 2009

... 1 clinical trial in 2009; -- MT293, a humanized monoclonal antibody targeting denatured collagen, in development by Tracon Pharmaceuticals, Inc. for the ... arthritis, psoriasis, or multiple sclerosis. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of ...

YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia

... observed in all of the other antibodies and with small molecules targeting the EGF tyrosine kinase signaling pathway. Unrelated to the rash, Grade ... of free and liposome-encapsulated fentanyl. Nimotuzumab is in development targeting multiple tumour types in combination with radiation, chemoradiation and ...

AFFiRiS Begins Development of a Parkinson's Vaccine

... enables us to develop vaccines that induce antibody specifically targeting alpha-syn only." Frank Mattner, Chief Scientific Officer at AFFiRiS, ... project." The AFFITOME technology from AFFiRiS provides a means of targeting very specific structures of human rogue proteins with patented product ...

Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme

... ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and ... is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and ...

Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target

... ), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that Roche has dosed the first ... is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and ...

Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream

... / partner its only remaining program -- the CB2 Selective Agonist program targeting pain and inflammation. No further development work is being conducted on ... compounds from Pharmos' pipeline have completed preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease ...

Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA

... Discovery and SAR of a Novel Series of Pyrimidine Antibacterials targeting Methionyl-tRNA Synthase (MetRS) -- F1-335: In Vitro Activity of Rx100472 ... pm) -- F2-2070: Structure Guided Design of Pyrimidine Antibacterials targeting Methionyl-tRNA Synthase (MetRS) Copies of these posters will be ...

In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop

... testing Taligen's product candidates are highlighted below: Data support targeting the alternative complement pathway using TT30 as an immunomodulatory ... Besides adding further confirmation to the therapeutic potential of targeting the alternative pathway in complement-mediated diseases, the study showed ...

AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108

... of anticancer activity we have seen in our phase 1 study with this new targeting concept we developed in collaboration with the Nobel Prize laureate Dr. ... complete or partial response. About AEZS-108 AEZS-108 represents a new targeting concept in oncology using a cytotoxic peptide conjugate which is a hybrid ...